Matthew Gall
Net Worth
Last updated:
What is Matthew Gall net worth?
The estimated net worth of Mr. Matthew Gall is at least $3,408,846 as of 19 Nov 2024. He owns shares worth $662,796 as insider, has earned $232,250 from insider trading and has received compensation worth at least $2,513,800 in iTeos Therapeutics, Inc..
What is the salary of Matthew Gall?
Mr. Matthew Gall salary is $628,450 per year as Chief Financial Officer in iTeos Therapeutics, Inc..
How old is Matthew Gall?
Mr. Matthew Gall is 48 years old, born in 1977.
What stocks does Matthew Gall currently own?
As insider, Mr. Matthew Gall owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) | Chief Financial Officer | 65,429 | $10.13 | $662,796 |
What does iTeos Therapeutics, Inc. do?
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Matthew Gall insider trading
iTeos Therapeutics, Inc.
Mr. Matthew Gall has made only one insider trade between 2021-2024, according to the Form 4 filled with the SEC. He purchased 5,000 units of ITOS stock worth $38,635 on 19 Nov 2024.
As of 19 Nov 2024 he still owns at least 65,429 units of ITOS stock.
iTeos Therapeutics key executives
iTeos Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Joanne Jenkins Lager M.D. (54) Chief Medical Officer
- Dr. Michel Detheux Ph.D. (59) Pres, Chief Executive Officer & Director
- Mr. Matthew Gall (48) Chief Financial Officer